Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 17, Number 6—June 2011
Research

Multiple Introductions of Multidrug-Resistant Tuberculosis into Households, Lima, Peru

Ted CohenComments to Author , Megan B. Murray, Ibrahim Abubakar, Zibiao Zhang, Alexander Sloutsky, Fernando Arteaga, Katiuska Chalco, Molly F. Franke, and Mercedes C. Becerra
Author affiliations: Author affiliations: Brigham and Women’s Hospital, Boston, Massachusetts, USA (T. Cohen, M. Murray, Z. Zhang, M.C. Becerra); Harvard School of Public Health, Boston (T. Cohen, M. Murray); University of East Anglia, Norwich, UK (I. Abubakar); Health Protection Agency Centre for Infections, London, UK (I. Abubakar); University of Massachusetts Medical School, Boston (A. Sloutsky); Partners In Health, Boston and Lima, Peru (F. Arteaga, K. Chalco, M.F. Franke, M.C. Becerra); and Harvard Medical School, Boston (M.F. Franke, M.C. Becerra)

Main Article

Table A2

Persons with >1 distinct MDR Mycobacterium tuberculosis isolate, Lima, Peru, 1996–2004*

House ID no. Patient age, y/sex Date MIRU-VNTR pattern Spoligotype ST Lineage Drug susceptibility,
SHRECFYTKZALP†
192
 23/F
 2001 May 31 2 1 5 3 3 2 3 1 2 4 1 2 2 2 1 4 3 4 1 5 3 3 8 2 777777607760731 60 LAM4 RRRRSSSRSRXSS
2002 May 16
 + 2 4 3 3 2 4 3 2 6 1 3 3 2 1 4 3 4 2 1 2 + 6 2
 576177607760771
 1354
 LAM3
 RRRRSSSSSRSSS
439
 19/M
 2002 Apr 26 3 1 4 3 3 2 3 3 2 1 1 5 3 2 4 3 3 4 2 3 4 3 2 2 777777777460771 1905 T1 RRRRSSSSSRSSS
2002 Jun 17
 2 2 4 3 2 1 4 3 2 6 1 5 3 2 2 4 4 4 1 3 3 2 5 2
 777777407560731
 1355
 T2
 RRRRSSSSSRSSS
976
 26/M
 2000 Nov 28 4 2 4 3 2 2 3 3 2 1 1 5 3 2 4 3 3 4 2 3 4 3 2 2 777777777760771 53 T1 RRRRSSSRSRXSR
2001 Jan 22 4 2 4 3 2 2 3 3 2 1 1 5 3 2 4 3 3 4 2 3 4 3 2 2 777777777760771 53 T1 SRRRSSSRSXXSR
2001 Feb 2 4 2 4 3 2 2 3 3 2 1 1 5 3 2 4 3 3 4 2 3 4 3 2 2 777777777760771 53 T1 SRRRSSSSSXXSS
2001 Jun 4 4 2 4 3 2 2 3 3 2 1 1 5 3 2 4 3 3 4 2 3 4 3 2 2 777777777760771 53 T1 SRRRSSSSSRXSS
2002 Mar 30
 3 2 3 3 3 2 3 3 2 5 1 4 3 2 2 5 3 4 4 3 4 7 6 3
 700036777760771
 91
 X3
 RRRRSSSSRRRSS
977
 46/F
 NA 4 2 4 3 5 2 3 3 2 5 1 7 3 3 3 5 5 4 4 3 4 6 8 2 000000000003731 190 Beijing SRRRSSSRRRSSS
2000 Apr 11 2 2 4 3 3 2 4 + 2 6 1 5 3 2 3 3 3 4 2 1 2 3 7 2 776177607660731 ND ND SRRRSSSSSSXXX
2001 May 15
 2 2 4 3 3 2 4 3 2 6 1 5 3 2 3 3 3 4 2 1 2 4 7 2
 776177607660731
 ND
 ND
 SRRRSSSSSSSSS
977 20/M 2001 Aug 13 2 2 4 3 3 2 4 3 2 6 1 5 3 2 3 3 3 4 2 1 2 3 7 2 776377617660731 ND ND SRRRSSSSSSSSS
2001 Dec 3 2 2 4 3 3 2 4 3 2 6 1 5 3 2 3 3 3 4 2 1 2 3 7 2 776177607660731 ND ND SRRSSSSSSSSSS
2002 Jul 5 2 2 4 3 3 2 4 3 2 6 1 5 3 2 3 3 3 4 2 1 2 3 7 2 776177607660731 ND ND RRRRSSSRSSSSS

*MDR, multidrug resistant; ID, identification, MIRU-VNTR, mycobacterial interspersed repetitive unit–variable number tandem repeat; ST, shared type; NA, not available; ND, not determined because ST and lineage could not be assigned on the basis of spoligotype.
†Antimicrobial drugs tested were streptomycin (S), isoniazid (H), rifampin (R), ethambutol (E), capreomycin (C), ciprofloxacin (F), cycloserine (Y), ethionamide (T), kanamycin (K), pyrazinamide (Z), amikacin (A), levofloxacin (L), and p-amino salicylic acid (P). Susceptibility patterns: S, susceptible; R, resistant; X, no result.

Main Article

Page created: August 03, 2011
Page updated: August 03, 2011
Page reviewed: August 03, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external